Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study | ||
| dc.conicet.organizacion | Care Hospital Hyderabad | |
| dc.conicet.organizacion | Research and Scientific Center Sultan Bin Abdulaziz Humanitarian City | |
| dc.conicet.organizacion | Adnan Menderes Universitesi | |
| dc.conicet.organizacion | Sanofi | |
| dc.conicet.organizacion | Sanofi | |
| dc.conicet.organizacion | Sanofi | |
| dc.conicet.organizacion | University Malaya Medical Centre | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo | |
| dc.conicet.organizacion | Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín | |
| dc.contributor.author | Sethi, Bipin | |
| dc.contributor.author | Al-Rubeaan, Khalid | |
| dc.contributor.author | Unubol, Mustafa | |
| dc.contributor.author | Mabunay, Maria A. | |
| dc.contributor.author | Berthou, Baptiste | |
| dc.contributor.author | Pilorget, Valerie | |
| dc.contributor.author | Vethakkan, Shireene R. | |
| dc.contributor.author | Frechtel, Gustavo Daniel | |
| dc.date.issued | 2022-07 | |
| dc.description.abstract | Introduction: The efficacy and safety of switching to insulin glargine 300 U/mL (Gla-300) in type 2 diabetes mellitus (T2DM) uncontrolled on basal insulin (BI) has been demonstrated in the North American and Western European populations; however, there is limited data from other geographical regions with different ethnicities. The ARTEMIS-DM study aimed to evaluate the efficacy and safety of Gla-300 in people with T2DM uncontrolled on BI from Asia, Latin America and Middle East Africa. Methods: The ARTEMIS-DM was a 26-week, prospective, interventional, single-arm, phase IV study (NCT03760991). Adults with T2DM previously uncontrolled (glycated haemoglobin [HbA1c] 7.5–10%) on BI were switched to Gla-300. The primary endpoint was change in HbA1c from baseline to 26 weeks. Key secondary endpoints were changes in HbA1c (week 12), fasting plasma glucose (FPG), self-monitored plasma glucose (SMPG) and BI dose from baseline to week 26. The safety and tolerability of Gla-300 were also assessed. Results: A total of 372 (50% male) participants were included, with mean (standard deviation [SD]) age 60.9 (10.0) years, duration of diabetes 13.11 (7.48) years and baseline HbA1c 8.67 (0.77)% (71.22 [8.44] mmol/mol). A total of 222 (59.7%) participants were using insulin glargine 100 U/mL and 107 (28.8%) were using neutral protamine Hagedorn insulin as previous BI. There were clinically significant reductions in mean HbA1c (− 0.82%; primary endpoint), FPG and SMPG levels at week 26. With a pre-defined titration algorithm, mean Gla-300 dose increased from 27.48 U (0.35 U/kg) at baseline to 39.01 U (0.50 U/kg) at week 26. Hypoglycaemia events occurred in 20.4% of the participants; 1 (0.3%) participant had a severe hypoglycaemia event. Conclusion: In people with T2DM uncontrolled on previous BI, switching to Gla-300 with optimal titration guided by an algorithm was associated with improved glycaemic control and low incidence of hypoglycaemia across multiple geographic regions. ClinicalTrials.gov identifier: NCT03760991. | es |
| dc.description.fil | Fil: Sethi, Bipin. Care Hospital Hyderabad; India | |
| dc.description.fil | Fil: Al-Rubeaan, Khalid. Research and Scientific Center Sultan Bin Abdulaziz Humanitarian City; Argentina | |
| dc.description.fil | Fil: Unubol, Mustafa. Adnan Menderes Universitesi; Turquía | |
| dc.description.fil | Fil: Mabunay, Maria A.. Sanofi; Singapur | |
| dc.description.fil | Fil: Berthou, Baptiste. Sanofi; Francia | |
| dc.description.fil | Fil: Pilorget, Valerie. Sanofi; Francia | |
| dc.description.fil | Fil: Vethakkan, Shireene R.. University Malaya Medical Centre; Malasia | |
| dc.description.fil | Fil: Frechtel, Gustavo Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Sethi, Bipin; Al-Rubeaan, Khalid; Unubol, Mustafa; Mabunay, Maria A.; Berthou, Baptiste; et al.; Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study; Springer; Diabetes Therapy; 13; 7; 7-2022; 1395-1408 | es |
| dc.identifier.eissn | 1869-6961 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 1869-6953 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/216689 | |
| dc.journal.ciudad | Berlín | es |
| dc.journal.number | 7 | es |
| dc.journal.pagination | 1395-1408 | es |
| dc.journal.pais | Alemania | es |
| dc.journal.title | Diabetes Therapy | es |
| dc.journal.volume | 13 | es |
| dc.language.iso | eng | es |
| dc.publisher | Springer | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007/s13300-022-01271-7 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s13300-022-01271-7 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc/2.5/ar/ | * |
| dc.subject | BASAL INSULIN | es |
| dc.subject | GLYCAEMIC CONTROL | es |
| dc.subject | HYPOGLYCAEMIA | es |
| dc.subject | INSULIN GLARGINE 300 U/ML | es |
| dc.subject | TYPE 2 DIABETES MELLITUS | es |
| dc.subject.classification | Endocrinología y Metabolismo | es |
| dc.subject.classification | Medicina Clínica | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Efficacy and Safety of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Uncontrolled on Basal Insulin: The 26-Week Interventional, Single-Arm ARTEMIS-DM Study | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.b3d3f411-8d9d-4a08-b247-1d3bde39bcf7_B.pdf
- Tamaño:
- 571.21 KB
- Formato:
- Adobe Portable Document Format